✦ LIBER ✦

A phase I study of T900607 given once every three weeks in patients with advanced refractory cancer. A National Cancer Institute of Canada-Clinical Trials Group Study (NCIC CTG-IND 130)

✍ Scribed by K.A. Gelmon; K. Belanger; C. Britton; D. Soulières; S. Janke; J. Dionne; J. Powers; L.K. Seymour; J. McNally

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of ZD0473 and docetaxel

✍ K.A. Gelmon; D. Stewart; D. Ayers; D. Fry; L. Douglas; L.W. McIntosh; L.K. Seymo 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 172 KB

A phase II trial of zd0473 in patients w

✍ T.A. Vandenberg; K.A. Gelmon; L. Panasci; M. Crump; B. Norris; A. Tomiak; T. She 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 166 KB

Phase II study of docetaxel (taxotere) i

📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 133 KB

A National Cancer Institute of Canada Cl

✍ J.A. Maroun; D. Jonker; L. Seymour; R. Goel; M. Vincent; W. Kocha; C. Cripps; B. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 131 KB

A phase I study of BAY 38-3441 given as

✍ L. Seymour; L. Siu; G. Batist; J. Cammisano; M. Maclean; L. McIntosh; O. Petrenc 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 189 KB

Phase I study of triple drug combination

✍ Maroun, J.A.; Jonker, D.; Seymour, L.; Goel, R.; Kocha, W.; Fisher, B. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 206 KB